Schmidt P J Investment Management Inc. Boosts Stock Position in Boston Scientific Corporation $BSX

Schmidt P J Investment Management Inc. increased its stake in Boston Scientific Corporation (NYSE:BSX) by 36.9% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,408 shares of the medical equipment provider’s stock after buying an additional 3,887 shares during the period. Schmidt P J Investment Management Inc.’s holdings in Boston Scientific were worth $1,548,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. 1248 Management LLC purchased a new stake in shares of Boston Scientific in the 1st quarter worth approximately $26,000. Y.D. More Investments Ltd purchased a new stake in shares of Boston Scientific in the 1st quarter worth approximately $27,000. Sound Income Strategies LLC grew its stake in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 120 shares during the last quarter. Princeton Global Asset Management LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $32,000. Finally, Oliver Lagore Vanvalin Investment Group purchased a new stake in Boston Scientific during the 2nd quarter valued at $37,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Leerink Partners increased their target price on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Canaccord Genuity Group reiterated a “buy” rating and set a $132.00 target price on shares of Boston Scientific in a research note on Thursday. Erste Group Bank downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Finally, Truist Financial increased their target price on Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $123.77.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 170,214 shares of company stock worth $17,548,337. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

BSX stock opened at $101.08 on Monday. The company has a market cap of $149.78 billion, a P/E ratio of 54.06, a price-to-earnings-growth ratio of 2.04 and a beta of 0.61. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The stock’s fifty day moving average price is $101.14 and its 200-day moving average price is $102.12.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same period last year, the business posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.